Clinical Trial

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Study acronym: CROSSCHECK-001
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Participants aged ≥ 12 years are planned to be enrolled. CBX-250 will initially be investigated on a fixed step-up dosing schedule. CBX-250 will be administered subcutaneously in 28-day cycles, with the first study drug dose administered on Cycle 1, Day 1. Cycle 1 will consist of a priming phase over 7 days, and a target phase over 28 days. Participants will continue CBX-250 until progressive disease (PD) or unacceptable toxicity. All subsequent treatment cycles will be 28 days.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-05-20; most recent amendment 2026-03-12.
Status change: Not Yet Recruiting → Recruiting 2025-07-08
Trial Details
NCT Number NCT06994676
Lead Sponsor Crossbow Therapeutics, Inc.
Conditions High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML - Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Enrollment 72 participants
Start Date 2025-07-16
Primary Completion 2027-01 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-16